224 related articles for article (PubMed ID: 18240909)
1. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
Thervet E; Legendre C; Beaune P; Anglicheau D
Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
[TBL] [Abstract][Full Text] [Related]
3. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
4. [Cytochrome P450 3A polymorphism and its importance in cyclosporine and tacrolimus therapy in transplanted patients].
Duricová J; Grundmann M
Ceska Slov Farm; 2007 Oct; 56(5):220-4. PubMed ID: 18064802
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
Coto E; Tavira B
Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies.
Anglicheau D; Legendre C; Thervet E
Transplant Proc; 2007 Sep; 39(7):2142-4. PubMed ID: 17889118
[TBL] [Abstract][Full Text] [Related]
8. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
9. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
Masuda S; Inui K
Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
[TBL] [Abstract][Full Text] [Related]
11. Genetic factors for individual administration of immunosuppressants in organ transplantation.
Yu SF; Wu LH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
13. Use of pharmacogenetics to optimize immunosuppressive therapy.
Macphee IA
Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
15. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
Kniepeiss D; Renner W; Trummer O; Wagner D; Wasler A; Khoschsorur GA; Truschnig-Wilders M; Tscheliessnigg KH
Clin Transplant; 2011; 25(1):146-50. PubMed ID: 20041908
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
[TBL] [Abstract][Full Text] [Related]
17. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
Lemaitre F; Bezian E; Goldwirt L; Fernandez C; Farinotti R; Varnous S; Urien S; Antignac M
Ther Drug Monit; 2012 Dec; 34(6):686-94. PubMed ID: 23131698
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms and individualized tacrolimus dosing.
López-Montenegro Soria MA; Kanter Berga J; Beltrán Catalán S; Milara Payá J; Pallardó Mateu LM; Jiménez Torres NV
Transplant Proc; 2010 Oct; 42(8):3031-3. PubMed ID: 20970601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]